Azenta Reports Q3 Revenue of $143.9 Million, Net Loss of $52.8 Million

Azenta, Inc. reported its financial results for the third quarter and nine months ended June 30, 2025, revealing a total revenue of $143.9 million for the quarter, a slight decrease of 0.2% compared to $144.3 million in the same period last year. For the nine-month period, revenue increased by 3% to $434.9 million from $422.4 million. The company's gross profit for the quarter was $67.8 million, resulting in a gross margin of 47%, consistent with the previous year. However, the company experienced a net loss of $52.8 million for the quarter, compared to a loss of $6.6 million in the prior year, primarily due to significant losses from discontinued operations related to the planned sale of its B Medical Systems business.

In terms of operational performance, Azenta's Sample Management Solutions segment saw a revenue decline of 3.7% for the quarter, while the Multiomics segment reported a 4.1% increase. The overall revenue growth for the nine-month period was driven by strong performance in Sample Repository Solutions and Next Generation Sequencing services. The company’s operating expenses decreased to $68.5 million for the quarter, down from $72.6 million a year earlier, largely due to reduced research and development costs. The operating loss for the quarter was $0.7 million, an improvement from a loss of $7.1 million in the same quarter last year.

Azenta's strategic focus includes the planned divestiture of its B Medical Systems business, which has been classified as a discontinued operation. The company recorded a loss of $68.8 million on assets held for sale during the quarter, contributing to the overall net loss. The decision to sell this segment is aimed at simplifying the company's portfolio and enhancing focus on its core Sample Management Solutions and Multiomics segments. The company anticipates finalizing the sale by November 2025.

As of June 30, 2025, Azenta reported total assets of $2.02 billion, a decrease from $2.10 billion at the end of the previous fiscal year. The company had cash and cash equivalents of $270 million, down from $280 million, and total stockholders' equity of $1.67 billion. The company employed approximately 3,000 individuals globally and generated 39% of its revenue from international markets during the quarter. Looking ahead, Azenta remains focused on operational efficiencies and strategic growth opportunities, while managing the impacts of market conditions and ongoing restructuring efforts.